Skip to main content
Clinical Trials/JPRN-jRCT2080220543
JPRN-jRCT2080220543
Unknown
Phase 3

A Long Term Study to Investigate the Efficacy and Safety Study of D961H (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use

AstraZeneca0 sitesApril 9, 2008

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
AstraZeneca
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 9, 2008
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Ages Eligible for Study: 20 Years and older
  • Genders Eligible for Study: Both
  • Accepts Healthy Volunteers: No
  • Inclusion Criteria:
  • \-Medical history of gastric and/or duodenal ulcer
  • \-A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age

Exclusion Criteria

  • \-Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification
  • \-History of esophageal, gastric or duodenal surgery
  • \-Having severe liver disease or chronic renal disease

Outcomes

Primary Outcomes

Not specified

Similar Trials